But with Brukinsa and degraders looming, will fixed dosing make the difference?

Crossover scuppers Jaypirca's survival benefit, but full approval seems likely.

Enzomenib might be the most promising agent so far, on a cross-trial basis.

The group presents data with bleximenib plus chemo, but looks behind Kura’s contender.

Phase 2 data show why Merck took the lowest dose of zilo-V into phase 3.

Etentamig is one of several anti-BCMA T-cell engagers seeking attention at ASH.

The group claims a seven-day vein-to-vein time is unique, and says why this matters.

And the company might one day follow Galapagos into decentralised manufacturing.

JNJ-89853413 is disclosed as the lead in the two companies' 2020 alliance.